Plain-English translation of NCT03356795 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new type of immunotherapy called CAR-T cells for people with advanced or recurrent cervical cancer. Doctors will collect some of your immune cells (called T cells), modify them in a laboratory to recognize and attack cervical cancer cells, and then infuse them back into your body. The goal is to see if this treatment is safe and effective at slowing or stopping the cancer.
Cervical cancer remains a serious disease worldwide, and current treatments like surgery, radiation, and chemotherapy don't work for everyone—especially those with advanced or recurring cancer. This trial is exploring whether training your own immune system to attack cancer cells could offer a new option for patients who need additional help.
If you qualify, doctors will draw your blood to collect immune cells in a procedure called apheresis. Your T cells will then be sent to a laboratory where they are genetically modified to recognize your specific cancer. While the cells are being modified (which takes weeks), you will have clinic visits to monitor your health. Once the modified cells are ready, you will receive them back through an IV infusion, and doctors will follow you closely with blood tests and scans to watch for side effects and see how well the treatment works.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Shenzhen Geno-Immune Medical Institute
Enrollment target
~20 participants
Started
June 2026
Primary completion
July 2026
Age range
18 Years – 70 Years
Sex
Female only
Last updated on clinicaltrials.gov in August 2026.